The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

類似資料

• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
  著者:: Byrd, John C, 等
  出版事項: (2015)
• Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
  著者:: Wu, Jingjing, 等
  出版事項: (2016)
• Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells
  著者:: Patel, Viralkumar, 等
  出版事項: (2016)
• Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
  著者:: Abbas, Hussein A., 等
  出版事項: (2021)
• Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
  著者:: Introna, Martino, 等
  出版事項: (2020)